USFDA approves SAPIEN 3 Transcatheter Heart Valve
Advertisement
The U.S. Food and Drug Administration (USFDA) states it’s approval of the third generation of the SAPIEN THV, which was originally approved in 2011. This edition of the SAPIEN family, to be launched after receiving the approval from FDA on June 17, 2015 is the SAPIEN 3 Transcatheter Heart Valve (THV). Directed to provide solutions for patients, with a narrowing in the heart's aortic valve called aortic valve stenosis; Aortic valve stenosis obstructs blood flow from the heart into the aorta, which can lead to serious heart problems. This medical device is highly recommended for patients, who suffer from severe aortic valves tenosis, and are inoperable or are perceive to have complications associated with open-heart surgery.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.